Keybank National Association OH Buys 517,666 Shares of Kenvue Inc. (NYSE:KVUE)

Keybank National Association OH increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 12.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,675,727 shares of the company’s stock after acquiring an additional 517,666 shares during the quarter. Keybank National Association OH owned approximately 0.24% of Kenvue worth $99,827,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. FMR LLC boosted its position in shares of Kenvue by 2.3% during the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after purchasing an additional 3,075,019 shares in the last quarter. State Street Corp lifted its holdings in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after purchasing an additional 7,115,374 shares during the period. Geode Capital Management LLC increased its stake in Kenvue by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock valued at $1,029,810,000 after purchasing an additional 399,846 shares in the last quarter. Finally, Harris Associates L P raised its holdings in Kenvue by 7.5% during the third quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock worth $727,658,000 after buying an additional 2,186,114 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 0.8 %

KVUE opened at $23.79 on Tuesday. The company’s 50-day moving average price is $21.50 and its two-hundred day moving average price is $22.29. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The stock has a market cap of $45.47 billion, a price-to-earnings ratio of 44.89, a PEG ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.45%. Kenvue’s dividend payout ratio is presently 154.72%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group reduced their price objective on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a report on Friday, February 7th. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Barclays decreased their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $23.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.